Switch theme

🎉 M&A multiples are live!
Check it out!

Genetic Analysis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genetic Analysis and similar public comparables like Healius, Cyclopharm, and Clarity Pharmaceuticals.

All Medical Imaging & Diagnostics Multiples Start Free Trial
Genetic Analysis logo Genetic Analysis logo

Sign up to access all valuation multiples

Genetic Analysis Overview

About Genetic Analysis

Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world.

Founded

2008

HQ

Sweden
Employees

16

Financials

Last FY Revenue $1.6M

Last FY EBITDA -$0.9M

EV

$6.1M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Genetic Analysis Financials

In the most recent fiscal year, Genetic Analysis achieved revenue of $1.6M and an EBITDA of -$0.9M.

Genetic Analysis expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Genetic Analysis valuation multiples based on analyst estimates

Genetic Analysis P&L

NTM Last FY FY 2025 FY 2026 FY 2027
Revenue XXX $1.6M XXX XXX XXX
Gross Profit XXX $1.3M XXX XXX XXX
Gross Margin XXX 80% XXX XXX XXX
EBITDA XXX -$0.9M XXX XXX XXX
EBITDA Margin XXX -58% XXX XXX XXX
EBIT XXX -$1.3M XXX XXX XXX
EBIT Margin XXX -85% XXX XXX XXX
Net Profit XXX -$1.5M XXX XXX XXX
Net Margin XXX -93% XXX XXX XXX
Net Debt XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Genetic Analysis Stock Performance

As of July 3, 2025, Genetic Analysis's stock price is NOK 1 (or $0).

Genetic Analysis has current market cap of NOK 63.9M (or $6.3M), and EV of NOK 61.1M (or $6.1M).

See Genetic Analysis trading valuation data

Genetic Analysis Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$6.1M $6.3M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Genetic Analysis Valuation Multiples

As of July 3, 2025, Genetic Analysis has market cap of $6.3M and EV of $6.1M.

Genetic Analysis's trades at 3.8x EV/Revenue multiple, and -6.7x EV/EBITDA.

Equity research analysts estimate Genetic Analysis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Genetic Analysis's P/E ratio is not available.

See valuation multiples for Genetic Analysis and 12K+ public comps

Genetic Analysis Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $6.3M XXX $6.3M XXX XXX XXX
EV (current) $6.1M XXX $6.1M XXX XXX XXX
EV/Revenue n/a XXX 3.8x XXX XXX XXX
EV/EBITDA n/a XXX -6.7x XXX XXX XXX
EV/EBIT n/a XXX -4.5x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E n/a XXX -4.3x XXX XXX XXX
EV/FCF n/a XXX -5.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genetic Analysis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Genetic Analysis Margins & Growth Rates

Genetic Analysis's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Genetic Analysis's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genetic Analysis's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Genetic Analysis and other 12K+ public comps

Genetic Analysis Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX -58% XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $0.1M XXX XXX XXX
Opex per Employee XXX XXX $0.2M XXX XXX XXX
S&M Expenses to Revenue XXX XXX 3% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX 166% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms
Explore Valuation Multiples by Industry
Start Free Trial

Genetic Analysis Public Comps

See public comps and valuation multiples for Medical Imaging & Diagnostics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Australian Clinical Labs XXX XXX XXX XXX XXX XXX
Clarity Pharmaceuticals XXX XXX XXX XXX XXX XXX
CurveBeam AI XXX XXX XXX XXX XXX XXX
Cyclopharm XXX XXX XXX XXX XXX XXX
Healius XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Genetic Analysis M&A and Investment Activity

Genetic Analysis acquired  XXX companies to date.

Last acquisition by Genetic Analysis was  XXXXXXXX, XXXXX XXXXX XXXXXX . Genetic Analysis acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Genetic Analysis

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Genetic Analysis

When was Genetic Analysis founded? Genetic Analysis was founded in 2008.
Where is Genetic Analysis headquartered? Genetic Analysis is headquartered in Sweden.
How many employees does Genetic Analysis have? As of today, Genetic Analysis has 16 employees.
Is Genetic Analysis publicy listed? Yes, Genetic Analysis is a public company listed on SAT.
What is the stock symbol of Genetic Analysis? Genetic Analysis trades under GEAN ticker.
When did Genetic Analysis go public? Genetic Analysis went public in 2021.
Who are competitors of Genetic Analysis? Similar companies to Genetic Analysis include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm.
What is the current market cap of Genetic Analysis? Genetic Analysis's current market cap is $6.3M
Is Genetic Analysis profitable? Yes, Genetic Analysis is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.

Start Free Trial 🎦 Book a Call